Previous close | 102.00 |
Open | 102.37 |
Bid | 101.29 x 400 |
Ask | 101.44 x 400 |
Day's range | 100.45 - 103.79 |
52-week range | 62.55 - 142.79 |
Volume | |
Avg. volume | 3,756,544 |
Market cap | 38.828B |
Beta (5Y monthly) | 1.59 |
PE ratio (TTM) | N/A |
EPS (TTM) | -12.33 |
Earnings date | 02 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 132.36 |
Moderna (MRNA) reachead $101.41 at the closing of the latest trading day, reflecting a -0.58% change compared to its last close.
China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue. Three Chinese companies - Walvax Biotechnology, CSPC Pharmaceutical Group and Stemirna Therapeutics - came up with mRNA vaccines that won limited emergency approvals in Asia. However, Walvax and CSPC are not currently manufacturing three of their China market shots, a China health official told Reuters.
In the latest trading session, Moderna (MRNA) closed at $103.44, marking a -0.34% move from the previous day.